{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:07:08Z","timestamp":1780409228405,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cabergoline (CAB) has shown to have benefic effects on the metabolism in different clinical settings but its metabolic role in acromegaly disease has not been studied yet. Aim of our study was to evaluate the impact of CAB on glucose metabolism and weight in patients with acromegaly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients with acromegaly undergoing continuous treatment with CAB for at least 6\u00a0months were retrospectively screened. Exclusion criteria were discontinuation of CAB for more than one month, change of antidiabetic or other therapy for acromegaly, concomitant untreated hormonal deficiency, initiation of pregnancy and\/or breastfeeding. All patients were evaluated in terms of biochemical disease control, glucose metabolism and weight at baseline (T0) and after the introduction of CAB therapy at 6 (T6) and 12\u00a0months (T12).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-six patients (15 females and 11 males) were evaluated at T0 and T6 and 19 patients (12 females and 7 males) were also evaluated at T12. Insulin-like growth factor I (IGF-I) and prolactin (PRL) levels were significantly lower at T6 and T12 compared to baseline (p\u2009&lt;\u20090.001 for IGF-I, p\u2009&lt;\u20090.05 for PRL) even if no further differences were observed between T12 and T6. Considering the entire cohort, no differences were appreciated regarding the metabolic parameters but a significant reduction in weight and body mass index (BMI) was observed at both T6 (p\u2009=\u20090.009 for weight, p\u2009=\u20090.021 for BMI) and T12 (p\u2009=\u20090.014 for weight, p\u2009=\u20090.017 for BMI) compared to baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results confirm the efficacy of CAB in providing a significant improvement in the biochemical disease control but do not demonstrate a marked benefit on glucose metabolism of acromegaly patients. In such patients, CAB appears to have a rapid effect on weight and BMI, with significant changes noticeable as early as 6\u00a0months and persisting for at least 12\u00a0months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02396-1","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T15:02:08Z","timestamp":1716562928000},"page":"3019-3028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-8586","authenticated-orcid":false,"given":"E.","family":"Varaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cuboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sibilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bioletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gramaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01360-1","author":"A Giustina","year":"2023","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2023) Consensus on criteria for acromegaly diagnosis and remission. Pituitary. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"key":"2396_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40618-021-01731-0","volume":"45","author":"F Bioletto","year":"2022","unstructured":"Bioletto F, Prencipe N, Berton AM et al (2022) Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test. J Endocrinol Invest 45:981\u2013987. https:\/\/doi.org\/10.1007\/s40618-021-01731-0","journal-title":"J Endocrinol Invest"},{"key":"2396_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P (2011) Place of Cabergoline in Acromegaly: A Meta-Analysis. J Clin Endocrinol Metab 96:1327\u20131335. https:\/\/doi.org\/10.1210\/jc.2010-2443","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1210\/jc.2011-2603","volume":"97","author":"CE Higham","year":"2012","unstructured":"Higham CE, Atkinson AB, Aylwin S et al (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187\u20131193. https:\/\/doi.org\/10.1210\/jc.2011-2603","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae003","author":"SA Urwyler","year":"2024","unstructured":"Urwyler SA, Samperi I, Lithgow K et al (2024) Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvae003","journal-title":"Eur J Endocrinol"},{"key":"2396_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102\u2013152. https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"key":"2396_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667\u2013674. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.12.029","volume":"109","author":"F Lopez Vicchi","year":"2016","unstructured":"Lopez Vicchi F, Luque GM, Brie B et al (2016) Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res 109:74\u201380. https:\/\/doi.org\/10.1016\/j.phrs.2015.12.029","journal-title":"Pharmacol Res"},{"key":"2396_CR9","first-page":"390","volume":"67","author":"SM Taghavi","year":"2012","unstructured":"Taghavi SM, Fatemi SS, Rokni H (2012) Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med J Malaysia 67:390\u2013392","journal-title":"Med J Malaysia"},{"key":"2396_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Guarnotta V et al (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf) 79:845\u2013852. https:\/\/doi.org\/10.1111\/cen.12204","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2396_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1463-1326.2011.01534.x","volume":"14","author":"CD Gibson","year":"2012","unstructured":"Gibson CD, Karmally W, McMahon DJ et al (2012) Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14:335\u2013340. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01534.x","journal-title":"Diabetes Obes Metab"},{"key":"2396_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Granieri L, Galdiero M et al (2013) Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98:299\u2013310. https:\/\/doi.org\/10.1159\/000357810","journal-title":"Neuroendocrinology"},{"key":"2396_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","volume":"7","author":"NA Pala","year":"2015","unstructured":"Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr 7:99. https:\/\/doi.org\/10.1186\/s13098-015-0094-4","journal-title":"Diabetol Metab Syndr"},{"key":"2396_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769744","volume":"12","author":"R Pirchio","year":"2021","unstructured":"Pirchio R, Auriemma RS, Solari D et al (2021) Effects of pituitary surgery and high-dose cabergoline therapy on metabolic profile in patients with prolactinoma resistant to conventional cabergoline treatment. Front Endocrinol (Lausanne) 12:769744. https:\/\/doi.org\/10.3389\/fendo.2021.769744","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2396_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230. https:\/\/doi.org\/10.1210\/jc.2008-1533","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR16","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2022) 2. classification and diagnosis of diabetes: standards of care in diabetes\u20142023. Diabetes Care 46:S19\u2013S40. https:\/\/doi.org\/10.2337\/dc23-S002","journal-title":"Diabetes Care"},{"key":"2396_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03678-z","author":"E Varaldo","year":"2024","unstructured":"Varaldo E, Cuboni D, Prencipe N et al (2024) Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia? Endocrine. https:\/\/doi.org\/10.1007\/s12020-023-03678-z","journal-title":"Endocrine"},{"key":"2396_CR18","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/jc.2004-2009","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972\u20131978. https:\/\/doi.org\/10.1210\/jc.2004-2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s11102-011-0369-1","volume":"15","author":"JA Brzana","year":"2012","unstructured":"Brzana JA, Yedinak CG, Delashaw JB et al (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15:562\u2013570. https:\/\/doi.org\/10.1007\/s11102-011-0369-1","journal-title":"Pituitary"},{"key":"2396_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ghir.2008.02.001","volume":"18","author":"EO Machado","year":"2008","unstructured":"Machado EO, Taboada GF, Neto LV et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389\u2013393. https:\/\/doi.org\/10.1016\/j.ghir.2008.02.001","journal-title":"Growth Horm IGF Res"},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1210\/jc.2008-1337","volume":"94","author":"A Bianchi","year":"2009","unstructured":"Bianchi A, Giustina A, Cimino V et al (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015\u20132022. https:\/\/doi.org\/10.1210\/jc.2008-1337","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-017-0792-z","volume":"20","author":"K Schilbach","year":"2017","unstructured":"Schilbach K, Strasburger CJ, Bidlingmaier M (2017) Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20:33\u201345. https:\/\/doi.org\/10.1007\/s11102-017-0792-z","journal-title":"Pituitary"},{"key":"2396_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"Alexopoulou O, Bex M, Kamenicky P et al (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17:81\u201389. https:\/\/doi.org\/10.1007\/s11102-013-0471-7","journal-title":"Pituitary"},{"key":"2396_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST et al (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2396_CR25","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.23.03960-X","author":"N Prencipe","year":"2023","unstructured":"Prencipe N, Motta G, Crespi CM et al (2023) Psychiatric disorders and anger in patients with controlled acromegaly. Minerva Endocrinol (Torino). https:\/\/doi.org\/10.23736\/S2724-6507.23.03960-X","journal-title":"Minerva Endocrinol (Torino)"},{"key":"2396_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM dos Santos Silva","year":"2011","unstructured":"dos Santos Silva CM, Barbosa FRP, Lima GAB et al (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 19:800\u2013805. https:\/\/doi.org\/10.1038\/oby.2010.150","journal-title":"Obesity (Silver Spring)"},{"key":"2396_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JOL (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152\u2013177. https:\/\/doi.org\/10.1210\/er.2008-0027","journal-title":"Endocr Rev"},{"key":"2396_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","volume":"20","author":"E Kuhn","year":"2017","unstructured":"Kuhn E, Chanson P (2017) Cabergoline in acromegaly. Pituitary 20:121\u2013128. https:\/\/doi.org\/10.1007\/s11102-016-0782-6","journal-title":"Pituitary"},{"key":"2396_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262\u2013276. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"2396_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","volume":"14","author":"K Berinder","year":"2011","unstructured":"Berinder K, Nystr\u00f6m T, H\u00f6ybye C et al (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14:199\u2013207. https:\/\/doi.org\/10.1007\/s11102-010-0277-9","journal-title":"Pituitary"},{"key":"2396_CR31","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio R, Graziadio C, Colao A et al (2022) Metabolic effects of prolactin. Front Endocrinol (Lausanne) 13:1015520. https:\/\/doi.org\/10.3389\/fendo.2022.1015520","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2396_CR32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA et al (2009) Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 6:1457\u20131466. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x","journal-title":"J Sex Med"},{"key":"2396_CR33","doi-asserted-by":"publisher","first-page":"1100007","DOI":"10.3389\/fendo.2023.1100007","volume":"14","author":"N Prencipe","year":"2023","unstructured":"Prencipe N, Marinelli L, Varaldo E et al (2023) Isolated anterior pituitary dysfunction in adulthood. Front Endocrinol (Lausanne) 14:1100007. https:\/\/doi.org\/10.3389\/fendo.2023.1100007","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2396_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09847-9","author":"Z Karaca","year":"2023","unstructured":"Karaca Z, Unluhizarci K, Kelestimur F (2023) Hypoprolactinemia does it matter? redefining the hypopituitarism and return from a mumpsimus. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-023-09847-9","journal-title":"Rev Endocr Metab Disord"},{"key":"2396_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S et al (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500\u20131508. https:\/\/doi.org\/10.1210\/jc.2008-2332","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-023-03339-1","volume":"81","author":"M Moustaki","year":"2023","unstructured":"Moustaki M, Paschou SA, Xekouki P et al (2023) Secondary diabetes mellitus in acromegaly. Endocrine 81:1\u201315. https:\/\/doi.org\/10.1007\/s12020-023-03339-1","journal-title":"Endocrine"},{"key":"2396_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I, Tomasik A, Zgliczy\u0144ski W (2022) Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25:180\u2013190. https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"key":"2396_CR38","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, Rowles S, Russell-Jones D et al (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459\u20132463. https:\/\/doi.org\/10.1210\/jc.2008-2086","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR39","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3390\/ijms21072568","volume":"21","author":"U Kumar","year":"2020","unstructured":"Kumar U, Singh S (2020) Role of somatostatin in the regulation of central and peripheral factors of satiety and obesity. Int J Mol Sci 21:2568. https:\/\/doi.org\/10.3390\/ijms21072568","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02396-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:16:03Z","timestamp":1731046563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02396-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare. Prof. Silvia Grottoli and Dr. Nunzia Prencipe are among the Members of the Editorial Board of the Journal of Endocrinological Investigation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was in accordance with the principles of the Declaration of Helsinki, approved by the local Ethical Committee and all the subjects gave their informed consent to the collection of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was approved by the local Ethics Committee and was in accordance with the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"All subjects gave their informed consent to the processing of their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}